DONE: Roche Buying Genentech

At least big pharma is a source of M&A fees. Following news that Merck is buying Schering Plough, Roche and Genentech have FINALLY ended an ongoing maiting dance, as the Swiss drugmaker will buy out Genentech for $47 billion. Genentech, formally a Roche subsidiary before being spun out, had resisted the sale for the longest time, but eventually given the market uncertainty and Roche’s tenacity, gave in.

NOW WATCH: Money & Markets videos

Want to read a more in-depth view on the trends influencing Australian business and the global economy? BI / Research is designed to help executives and industry leaders understand the major challenges and opportunities for industry, technology, strategy and the economy in the future. Sign up for free at research.businessinsider.com.au.